Galectin therapeutics inc (GALT)
Balance Sheet / Yearly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Dec'10
ASSETS
Current assets:
Cash and cash equivalents

43,328

47,480

50,337

52,043

6,972

8,253

10,136

10,497

3,988

3,053

6,958

9,127

13,644

15,362

16,059

18,003

22,356

25,846

21,319

26,362

29,349

29,128

31,201

34,423

36,594

10,489

9,715

5,099

7,018

9,364

11,059

13,130

15,314

6,397

7,944

7,984

5,891

Grant receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

234

Prepaid expenses and other current assets

556

729

136

652

511

579

394

541

685

766

53

202

353

432

53

239

425

554

183

305

611

533

90

87

151

198

27

88

137

153

89

85

115

104

51

71

70

Total current assets

43,884

48,209

50,473

52,695

7,483

8,832

10,530

11,038

4,673

3,819

7,011

9,329

13,997

15,794

16,112

18,242

22,781

26,400

21,502

26,667

29,960

29,661

31,291

34,510

36,745

10,687

9,742

5,187

7,155

9,517

11,148

13,215

15,429

6,501

7,995

8,055

6,195

Property and equipment, net

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

0

-

-

-

1

1

2

3

3

5

6

7

8

6

4

5

6

7

3

7

Equity method investment in Galectin Sciences, LLC

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10

63

130

-

-

-

-

-

-

-

-

-

-

-

-

Restricted cash and security deposit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6

-

69

69

69

64

64

59

Other assets

227

258

287

317

347

174

86

172

258

342

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6

6

6

-

-

-

-

-

-

-

-

Restricted cash and other long-term assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6

-

-

-

-

-

-

Intangible assets, net

-

-

-

-

-

-

-

-

-

0

-

-

-

1

3

5

7

8

10

12

14

15

17

19

21

23

24

26

28

30

33

34

35

36

37

38

39

Total assets

44,111

48,467

50,760

53,012

7,830

9,006

10,616

11,210

4,931

4,161

7,011

9,329

13,997

15,795

16,115

18,247

22,788

26,408

21,512

26,679

29,974

29,677

31,319

34,594

36,899

10,713

9,777

5,225

7,196

9,561

11,193

13,322

15,538

6,612

8,103

8,160

6,300

LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable

660

1,661

354

396

448

297

171

220

1,151

608

166

399

1,346

910

652

932

1,311

448

929

775

922

906

838

665

486

762

377

285

316

397

256

246

669

384

198

129

125

Accrued expenses and other

656

1,093

862

857

459

1,512

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses

-

-

-

-

-

-

1,475

1,148

1,132

2,292

4,175

3,045

3,016

2,802

3,435

2,636

1,939

845

797

1,065

369

729

542

1,413

1,451

1,651

1,226

1,129

1,152

1,161

1,186

1,254

1,266

1,551

417

376

537

Accrued dividends payable

-

66

0

66

0

299

-

67

-

68

-

68

-

68

-

68

-

67

-

68

-

68

-

69

-

73

-

79

-

80

-

80

-

80

-

81

48

Deferred income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

200

200

200

200

200

200

Warrant liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

861

Total current liabilities

1,316

2,820

1,216

1,319

907

2,108

1,646

1,435

2,283

2,968

4,341

3,512

4,362

3,780

4,087

3,636

3,250

1,360

-

-

1,291

1,703

1,380

2,147

1,937

2,486

1,603

1,493

1,468

1,638

1,442

1,780

2,135

2,215

815

786

1,771

Other liabilities

42

52

62

72

81

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

1

5

5

6

-

-

-

-

-

3

12

Total liabilities

1,358

2,872

1,278

1,391

988

2,108

1,646

1,435

2,283

2,968

4,341

3,512

4,362

3,780

4,087

3,636

3,250

1,360

1,726

1,908

1,291

1,703

1,380

2,147

1,937

2,486

1,604

1,498

1,473

1,644

1,442

1,780

2,135

2,215

815

789

1,783

Commitments and contingencies (Note 10)

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Stockholders' equity:
Undesignated stock, $0.01 par value; 20,000,000 shares authorized, 20,000,000 designated at March 31, 2020 and December 31, 2019, respectively

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Convertible preferred stock, value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

557

557

-

557

567

567

567

567

567

587

587

632

632

632

632

632

632

632

632

-

-

644

Common stock, $0.001 par value; 100,000,000 shares authorized at March 31, 2020 and December 31, 2019, 57,029,209 and 56,894,642 issued and outstanding at March 31, 2020 and December 31, 2019, respectively

56

56

56

56

45

41

41

41

38

36

36

35

35

33

29

29

28

28

23

23

23

22

22

22

22

18

18

16

16

16

16

16

16

13

77

74

11

Additional paid-in capital

260,382

259,673

258,357

257,678

209,845

194,130

192,843

190,602

179,359

173,363

172,053

170,539

169,548

166,721

162,176

159,788

158,947

157,504

147,338

146,217

145,256

139,531

137,518

136,239

135,030

102,841

99,500

91,394

81,806

80,535

79,719

78,583

77,517

66,367

65,533

63,289

54,075

Retained deficit

-219,945

-216,394

-211,191

-208,373

-205,308

-196,215

-192,866

-189,820

-185,711

-181,168

-178,381

-173,719

-168,910

-163,701

-158,524

-152,887

-147,060

-140,049

-135,083

-128,930

-123,999

-118,925

-114,890

-111,104

-

-101,965

-

-

-

-

-

-

-

-

-

-

-

Deficit accumulated during the development stage

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

107,373

-

98,850

95,131

83,490

80,018

77,310

74,325

71,341

69,137

65,419

63,080

56,424

Total stockholders' equity

41,030

43,872

47,759

49,898

5,119

5,175

7,247

8,052

925

-530

947

4,094

7,912

10,292

10,305

7,487

12,472

18,040

12,835

17,877

21,847

21,195

23,217

25,724

28,266

1,481

1,300

-3,089

-1,036

1,165

3,057

4,906

6,824

-2,125

823

915

-1,694

Total liabilities, redeemable convertible preferred stock and stockholders' equity

44,111

48,467

50,760

53,012

7,830

9,006

10,616

11,210

4,931

4,161

7,011

9,329

13,997

15,795

16,115

18,247

22,788

26,408

21,512

26,679

29,974

29,677

31,319

34,594

36,899

10,713

9,777

5,225

7,196

9,561

11,193

13,322

15,538

6,612

8,103

8,160

6,300

Series C 6% super dividend redeemable convertible preferred stock
Convertible preferred stock, value

1,723

1,723

1,723

1,723

1,723

1,723

-

-

-

1,723

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Series A 12% convertible preferred stock
Convertible preferred stock, value

537

537

537

537

537

537

-

-

-

557

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Series B-1 12% convertible preferred stock
Convertible preferred stock, value

-

-

0

0

0

1,761

-

-

-

1,761

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Series B-2 12% convertible preferred stock
Convertible preferred stock, value

-

-

0

0

0

3,697

-

-

-

3,697

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Series B-3 8% convertible preferred stock
Convertible preferred stock, value

-

-

0

0

0

1,224

-

-

-

1,224

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-